Based on promising efficacy in a single-arm study , a randomized phase II trial was designed to compare the efficacy and safety of adding rh-endostatin ( Endostar ) to first-line standard etoposide and carboplatin ( EC ) chemotherapy for treatment of extensive-stage small-cell lung cancer .